Weinrauch Larry A, Burger Andrew J, Aepfelbacher Franz, Lee Annette T, Gleason Ray E, D'Elia John A
Joslin Diabetes Center, Boston, MA, USA.
Metabolism. 2007 Nov;56(11):1453-7. doi: 10.1016/j.metabol.2007.05.016.
We hypothesized that correction of insulin deficiency by pulsatile intravenous insulin infusion in type 1 diabetes mellitus patients with nephropathy preserves renal function by mechanisms involving cardiac autonomic function, cardiac mass, or efficiency, or by hemostatic mechanisms. The control group (8 patients) received subcutaneous insulin (3-4 injections per day). The intravenous infusion group (10 patients) received three 1-hour courses of pulsed intravenous insulin infusion on a single day per week in addition to subcutaneous insulin. Laboratory measurements included 2-dimensional Doppler echocardiography, 24-hour ambulatory monitoring with heart rate variation analysis, platelet aggregation and adhesion, plasma fibrinogen, factor VII, von Willebrand factor, fibrinolytic activity, plasminogen activator inhibitor, and viscosity measured at baseline and 12 months. Blood pressure control was maintained preferentially with angiotensin-converting enzyme inhibitors. Ratio of carbon dioxide production to oxygen utilization was measured with each infusion and showed rapid increase from 0.8 to 0.9 (P = .005) at weekly treatments through 12 months. We observed an annualized decrease in creatinine clearance of 9.6 mL/min for controls vs 3.0 mL/min for infusion patients. Annualized fall in blood hemoglobin was 1.9 vs 0.8 g/dL, respectively (P = .013). There were no differences between the control and infusion group with respect to glycohemoglobin, advanced glycated end products, cholesterol, or triglycerides. No differences between the study groups for hemodynamic or hemostatic factors were evident. Blood pressures were not significantly different at baseline or 12 months. We conclude that although preservation of renal function with attenuation of loss of blood hemoglobin during 12 months of intravenous insulin infusion was associated with improvement in the efficiency of fuel oxidation as measured by respiratory quotient, this occurred without differences in metabolic/hemostatic factors, cardiac autonomic function, cardiac wall, or chamber size. Our hypothesis that preservation of renal function in type 1 diabetes mellitus patients with proteinuria by weekly pulsed insulin infusion involves mechanisms from the autonomic nervous system, cardiac size, and function, or elements of hemostasis was not confirmed.
我们推测,通过对1型糖尿病肾病患者进行静脉脉冲式胰岛素输注来纠正胰岛素缺乏,可通过涉及心脏自主神经功能、心脏质量或效率的机制,或通过止血机制来保护肾功能。对照组(8例患者)接受皮下胰岛素治疗(每天3 - 4次注射)。静脉输注组(10例患者)除皮下胰岛素外,每周单日接受3个1小时疗程的脉冲式静脉胰岛素输注。实验室测量包括二维多普勒超声心动图、24小时动态监测及心率变异性分析、血小板聚集和黏附、血浆纤维蛋白原、因子VII、血管性血友病因子、纤溶活性、纤溶酶原激活物抑制剂以及在基线和12个月时测量的黏度。优先使用血管紧张素转换酶抑制剂维持血压控制。每次输注时测量二氧化碳产生与氧气利用的比率,结果显示在为期12个月的每周治疗中,该比率从0.8迅速增加至0.9(P = .005)。我们观察到,对照组的肌酐清除率年化下降9.6 mL/分钟,而输注组患者为3.0 mL/分钟。血红蛋白年化下降分别为1.9和0.8 g/dL(P = .013)。在糖化血红蛋白、晚期糖基化终产物、胆固醇或甘油三酯方面,对照组和输注组之间没有差异。研究组在血流动力学或止血因素方面没有明显差异。基线或12个月时血压无显著差异。我们得出结论,尽管在静脉胰岛素输注的12个月期间,肾功能的保留以及血红蛋白损失的减轻与通过呼吸商测量的燃料氧化效率的改善相关,但这一过程在代谢/止血因素、心脏自主神经功能、心脏壁或腔室大小方面并无差异。我们关于通过每周脉冲式胰岛素输注来保护1型糖尿病蛋白尿患者肾功能涉及自主神经系统、心脏大小和功能或止血因素的假设未得到证实。